The use of thoracic endovascular aortic repair (TEVAR) for the management of uncomplicated type B aortic dissection (un‐TBAD) remains controversial. There is a lack of consensus over whether pre‐emptive TEVAR… Click to show full abstract
The use of thoracic endovascular aortic repair (TEVAR) for the management of uncomplicated type B aortic dissection (un‐TBAD) remains controversial. There is a lack of consensus over whether pre‐emptive TEVAR should be carried out in patients with un‐TBAD at risk of progression to complicated TBAD. We present a review of current evidence and seek to suggest criteria where endovascular intervention in un‐TBAD may prove beneficial relative to pharmacotherapy alone.
               
Click one of the above tabs to view related content.